Baird Bullish on Pharmacyclics (PCYC) Following ASCO Abstracts
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Buy Incyte Genomics, Inc. (INCY) and Pharmacyclics (PCYC) Into ASCO Meeting
May 15, 2014 8:46 AM EDTNomura analyst M. Ian Somaiya is telling clients to buy Incyte Genomics, Inc. (NASDAQ: INCY) and Pharmacyclics, Inc. (NASDAQ: PCYC) following ASCO abstracts and into the meeting.
Somaiya comments, "We are buyers of INCY and... More
Drugs Stocks on Watch Ahead of ASCO Abstracts Release
May 14, 2014 3:13 PM EDTAbstracts for ASCO's 50th annual meeting taking place May 30 through June 3 are expected to be release tonight at around 5 pm (Link Here).
Stocks on watch include Bristol-Myers Squibb Co. (NYSE: BMY), Merck & Co., Inc. (NYSE:... More
